Page last updated: 2024-11-03

prazosin and Body Weight

prazosin has been researched along with Body Weight in 80 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension."9.06Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986)
"The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months."9.06Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988)
"The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug."9.06Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987)
"Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator."9.06Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987)
"Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)."9.06Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987)
"In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension."9.06Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986)
"The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated."9.06Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986)
"The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated."7.68Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993)
"Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety."7.67Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986)
"Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure."7.66Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981)
"There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension."5.28Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992)
"Patients with essential hypertension were randomized to treatment with either prazosin or pinacidil, a new direct-acting vasodilator."5.06Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension. ( Solomon, RJ; Weinberg, MS, 1987)
"A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension."5.06Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986)
"The long-term treatment of essential hypertension with terazosin, a new once-a-day alpha 1-adrenergic blocking agent, was evaluated in 364 hypertensive patients who received total daily doses of 1 to 40 mg for 3 weeks to 56 months."5.06Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension. ( Estep, CB; Glassman, HN; Horton, JK; Jordan, DC; Luther, RR; Schmitz, PJ, 1988)
"The efficacy and tolerability of felodipine and prazosin were compared in a double-blind randomised parallel group study of 100 patients with moderately severe essential hypertension, treated concomitantly with a beta-blocking drug."5.06Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study. ( Anderson, A; Gibson, J; Jackson, B; Morgan, TO, 1987)
"Chronic responses of systemic hemodynamics and blood pressure counterregulatory ("pseudo-tolerance") mechanisms were investigated in matched groups of patients with essential hypertension after 1 month of vasodilator therapy with pinacidil (a direct arterial dilator), prazosin (an alpha 1-adrenergic blocking drug) or captopril (an angiotensin-converting enzyme inhibitor)."5.06Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. ( Izzo, JL; Kallay, MC; Larrabee, PS; Licht, MR; Radke, KJ; Smith, RJ, 1987)
"In a multicenter, double-blind, placebo-controlled study, the efficacy and safety of terazosin and prazosin were compared in patients with mild to moderate essential hypertension."5.06Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. ( Deger, G, 1986)
"The safety and efficacy of once-daily terazosin as monotherapy were evaluated in five randomized, double-blind, placebo-controlled studies in which 351 patients with mild to moderate hypertension participated."5.06Terazosin: an effective once-daily monotherapy for the treatment of hypertension. ( Dauer, AD, 1986)
" Addition of eugenosedin-A to the high-fat diet resulted in less weight gain and reduced hyperglycaemia, hyperinsulinaemia and hyperlipidaemia."3.75Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet. ( Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN, 2009)
"A novel model of hypertension recently developed in our laboratory shows that neonatal degeneration of capsaicin-sensitive sensory nerves renders a rat responsive to a salt load with a significant rise in blood pressure."3.70Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation. ( Li, J; Wang, DH, 1999)
"The stimulus for carbon monoxide-induced cardiac hypertrophy was investigated."3.68Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat. ( Formolo, JM; Penney, DG, 1993)
"The development of cardiac hypertrophy was examined in rats given ethanol in a nutritionally adequate, liquid diet mixture, by intubation, in severely intoxicating doses at 8-h intervals for up to 96 h, alone or in combination with prazosin."3.67Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy. ( Adams, MA; Hirst, M, 1989)
"The current study was designed to explore the effects of peripherally administered alpha-adrenoceptor inhibiting drugs (either prazosin or yohimbine) in spontaneously hypertensive (SHR) and DOCA-salt hypertensive rats before the development of established hypertension, as well as to characterize changes induced by prazosin and/or yohimbine in the cardiac noradrenaline (NA) content that might be responsible for the development of hypertension in these strains."3.67Alpha-blockade on blood pressure and on cardiac noradrenaline content in SHR and DOCA-salt rats. ( Saiz, J; Sanchez, A; Torres, A, 1989)
"Two hundred twenty-six patients with mild to moderate hypertension were treated with terazosin in an open, multicenter study to determine the drug's long-term efficacy and safety."3.67Long-term experience with terazosin for treatment of mild to moderate hypertension. ( Mersey, JH, 1986)
"The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies."3.67Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986)
"Prazosin was used as additional therapy in seven patients with severe chronic congestive cardiac failure."3.66Effect of prazosin on renal function in chronic congestive cardiac failure. ( Morgan, TO; Myers, JB; Walker, JN, 1981)
"Seventeen patients with newly diagnosed hypertension, or with hypertension not optimally controlled by previous treatment, completed an open, noncomparative study on the effects of prazosin on plasma lipids."3.66Open assessment of the effect of prazosin on plasma lipids. ( Flax, JS; Havard, CW; Khokhar, AM, 1982)
"In a dose-response study of prazosin in 24 patients with Raynaud's phenomenon, the clinical effectiveness and side effects of 3, 6, and 12 mg prazosin administered daily were compared."2.66Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. ( Thien, T; Wollersheim, H, 1988)
"Treatment with prazosin, an α1-adrenergic antagonist and vasodilator, increased tail temperature in control mice by up to 4."1.56The contribution of the mouse tail to thermoregulation is modest. ( Gavrilova, O; Guo, J; Liu, N; Reitman, ML; Škop, V, 2020)
"Prazosin was used as a reference compound, as quinazoline-based α1-adrenolytics may potentially exert unfavorable proapoptotic and necrotic effects."1.51Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist. ( Filipek, B; Kotańska, M; Kubacka, M; Marona, H; Mogilski, S; Nowak, B; Waszkielewicz, AM; Zadrożna, M, 2019)
"Tesofensine is a novel monoamine reuptake inhibitor that inhibits both norepinephrine, 5-HT, and dopamine (DA) reuptake function."1.36Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. ( Axel, AM; Hansen, HH; Mikkelsen, JD, 2010)
"Morphine withdrawal was precipitated by administration of naloxone (5 mg/kg subcutaneously) on day 8."1.32Changes in c-fos expression in the rat heart during morphine withdrawal. Involvement of alpha2-adrenoceptors. ( Aviles, M; González-Cuello, A; Laorden, ML; Milanés, MV, 2004)
"Hydralazine was the only drug to alter the lipid peroxidation level in the myocardium of SHR rats (a 28% decrease), but in WKY rats all three drugs caused significant decreases in myocardial lipid peroxidation levels."1.30Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. ( Cabell, KS; Johnson, P; Ma, L, 1997)
"High sodium diet (HS, 8% NaCl) induces left ventricular hypertrophy (LVH) in normotensive rats without an increase in pressure or volume load or in resting cardiac sympathetic activity."1.30alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy. ( Harmsen, E; Leenen, FH; Song, D, 1997)
" The dose-response relationship of cocaine with fetal development was established in CF-1 mice by administering cocaine sc on days 5 to 18 of gestation followed by teratologic evaluation."1.28Antagonism of cocaine-induced fetal anomalies by prazosin and diltiazem in mice. ( Hitner, HW; Mahalik, MP, 1992)
" In both the SHR and WKY, chronic administration of terazosin did not influence vascular concentrations of 3-methylhistidine, a biochemical marker for contractile proteins and vascular medial hypertrophy."1.28Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat. ( Frewin, DB; Head, RJ; Jonsson, JR, 1992)
"There is evidence that cardiac hypertrophy in spontaneously hypertensive rats (SHR) occurs before the development of hypertension."1.28Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. ( Asano, H; Hashimoto, H; Ishikawa, K; Ito, T; Kondo, J; Okumura, K; Yoshino, M, 1992)
"Doxazosin treatment partially prevented the accumulation of cholesterol and triglycerides in the liver."1.28Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster. ( Birkenhäger, JC; Jansen, H, 1991)
"Treatment with prazosin, an alpha 1-noradrenergic receptor antagonist, reduced Na+-K+-ATPase in either control or cafeteria diet-fed rats but did not alter the effect of cafeteria diet feeding."1.27Caloric intake and Na+-K+-ATPase: differential regulation by alpha 1- and beta-noradrenergic receptors. ( Swann, AC, 1984)
" When administered daily for 1 month at dosages of 0, 10, 40 or 150 mg/kg/day, the no-toxic-effect dosage was 40 mg/kg/day."1.27Terazosin: intravenous safety evaluation in rats. ( Cusick, PK; Fort, FL; Heyman, IA; Kesterson, JW; Majors, K; Tekeli, S, 1984)
"Renal hypertrophy was also decreased significantly by cicletanine at a dose of 100 mg/kg."1.27Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. ( Braquet, P; Clostre, F; Le Hegarat, M; Malherbe, E, 1988)
"Yohimbine was without effect in androgenized and nonandrogenized animals."1.27Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior. ( Döhler, KD; Geerlings, H; Jarzab, B; Sickmöller, PM, 1987)
"Prazosin was given after clonidine to the same patients in a dose range of 3 to 40 mg/day."1.26Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and beta-blocker-treated patients. ( Mitchell, HC; Pettinger, WA, 1981)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-199034 (42.50)18.7374
1990's27 (33.75)18.2507
2000's13 (16.25)29.6817
2010's5 (6.25)24.3611
2020's1 (1.25)2.80

Authors

AuthorsStudies
Škop, V1
Liu, N1
Guo, J1
Gavrilova, O1
Reitman, ML1
Kubacka, M1
Zadrożna, M1
Nowak, B1
Kotańska, M1
Filipek, B1
Waszkielewicz, AM1
Marona, H1
Mogilski, S1
Vickers, SP1
Hackett, D1
Murray, F1
Hutson, PH1
Heal, DJ1
Shen, KP1
Lin, HL1
Hsieh, SL1
Kwan, AL1
Chen, IJ1
Wu, BN1
Axel, AM1
Mikkelsen, JD1
Hansen, HH1
White, CW1
Short, JL1
Haynes, JM1
Matsui, M1
Ventura, S1
Kristek, F1
Koprdova, R1
Papay, R1
Zuscik, MJ1
Ross, SA1
Yun, J1
McCune, DF1
Gonzalez-Cabrera, P1
Gaivin, R1
Drazba, J1
Perez, DM1
Zaninovich, AA1
Rebagliati, I1
Raices, M1
Ricci, C1
Hagmuller, K1
Oben, JA1
Roskams, T1
Yang, S1
Lin, H1
Sinelli, N1
Li, Z1
Torbenson, M1
Huang, J1
Guarino, P1
Kafrouni, M1
Diehl, AM1
González-Cuello, A1
Milanés, MV1
Aviles, M1
Laorden, ML1
Farah, V1
Elased, KM1
Chen, Y1
Key, MP1
Cunha, TS1
Irigoyen, MC1
Morris, M1
Pérez, H2
Ruiz, S2
Núñez, H2
White, A2
Gotteland, M2
Hernández, A1
Tsai, YS1
Tong, YC1
Cheng, JT1
Lee, CH1
Yang, FS1
Lee, HY1
Latifpour, J1
McNeill, JH1
Swann, AC1
Raasmaja, A1
Mohell, N1
Nedergaard, J1
Mitchell, HC1
Pettinger, WA1
Havard, CW1
Khokhar, AM1
Flax, JS1
Williams, RS1
Schaible, TF1
Scheuer, J1
Kennedy, R1
Mills, PR1
Rae, AP1
Farah, DA1
Russell, RI1
Lorimer, AR1
Carter, DC1
Fort, FL1
Tekeli, S1
Majors, K1
Heyman, IA1
Cusick, PK1
Kesterson, JW1
Vardan, S1
Smulyan, H1
Mookherjee, S1
Eich, R1
Myers, JB1
Morgan, TO2
Walker, JN1
Imai, C1
Tozawa, M1
Sunagawa, O1
Muratani, H1
Takishita, S1
Fukiyama, K1
Nagano, T1
O'Harrow, S1
Sponer, G1
Zimmer, HG1
Semplicini, A1
Valle, R1
Serena, L1
Fazari, G1
Fontebasso, A1
Gebbin, A1
De Toni, R1
Pessina, AC1
Penner, SB2
Jeffery, JJ1
Smyth, DD2
Stanko, CK1
Penney, DG1
Formolo, JM1
Skúladóttir, GV1
Schiöth, HB1
Gudbjarnason, S1
Levin, BE1
Planas, B1
Routh, VH1
Hamilton, J1
Stern, JS1
Horwitz, BA1
Okuyama, N1
Morinobu, S1
Totsuka, S1
Endoh, M1
Sallés, J1
Gascón, S1
Badia, A1
Takada, S1
Numabe, A1
Hirawa, N1
Yagi, S1
Uehara, Y1
Chen, C1
Noland, KA1
Kalu, DN1
Song, D1
Harmsen, E1
Leenen, FH2
Cabell, KS1
Ma, L1
Johnson, P1
Wang, DH1
Li, J1
Obrosova, IG1
Van Huysen, C1
Fathallah, L1
Cao, X1
Stevens, MJ1
Greene, DA1
Tropia, FC1
Cardoso, LM1
Pedrosa, ML1
Silva, ME1
Haibara, AS1
Moraes, MF1
Chianca, DA1
Abete, P1
Testa, G1
Ferrara, N1
De Santis, D1
Capaccio, P1
Viati, L1
Calabrese, C1
Cacciatore, F1
Longobardi, G1
Condorelli, M1
Napoli, C1
Rengo, F1
Brown, RA1
Ilg, KJ1
Chen, AF1
Ren, J1
Keusch, G1
Weidmann, P2
Glück, Z1
Meier, A1
Beretta-Piccoli, C1
Jonsson, JR1
Head, RJ1
Frewin, DB1
Okumura, K1
Kondo, J1
Yoshino, M1
Ishikawa, K1
Asano, H1
Hashimoto, H2
Ito, T1
Fitch, RH1
Feder, H1
Mahalik, MP1
Hitner, HW1
Ferrari, P1
Rosman, J1
Neuner, N1
Shaw, S1
Riesen, W1
Jansen, H1
Birkenhäger, JC1
Inazu, M1
Sakai, Y1
Homma, I1
Jansson, JH1
Johansson, B1
Boman, K1
Nilsson, TK1
Nakamoto, H1
Suzuki, H1
Kageyama, Y1
Ohishi, A1
Murakami, M1
Naitoh, M1
Saruta, T1
Klement, G1
Pérez-Olea, J1
Prat, H1
Román, O2
Zarate, LH1
Cabello, H1
Quevedo, M1
Fuentes, S1
Reinback, R1
Chadid, P1
Itaya, T1
Satoh, R1
Uematsu, T1
Nakashima, M1
Bitar, M1
Koulu, M1
Rapoport, SI1
Linnoila, M1
Ames, RP1
Chrysant, SG1
Gonzalez, F1
Schnaper, HW1
Spann, S1
Velasquez, MT1
Adams, MA1
Hirst, M1
Sanchez, A2
Torres, A2
Saiz, J2
Ziada, A1
Hudlicka, O1
Tyler, KR1
Kaschube, M1
Möller-Hartmann, H1
Zetler, G1
Lara, B1
Geller, HS1
Nyhan, DP1
Goll, HM1
Clougherty, PW1
Chen, BB1
Murray, PA1
Dauer, AD1
Deger, G1
Mersey, JH1
Sperzel, WD1
Glassman, HN2
Jordan, DC2
Luther, RR2
Izzo, JL1
Licht, MR1
Smith, RJ1
Larrabee, PS1
Radke, KJ1
Kallay, MC1
Jarzab, B1
Sickmöller, PM1
Geerlings, H1
Döhler, KD1
Jackson, B1
Gibson, J1
Anderson, A1
Estep, CB1
Schmitz, PJ1
Horton, JK1
Nafstad, I1
Tollersrud, S1
Eriksen, K1
Helgeland, A1
Solberg, LA1
Bredesen, J1
Dale, O1
Torvik, D1
Madsbu, HP1
Malherbe, E1
Le Hegarat, M1
Clostre, F1
Braquet, P1
McCaughran, JA1
Juno, CJ1
Friedman, R1
Wollersheim, H1
Thien, T1
Solomon, RJ1
Weinberg, MS1
Sulakhe, SJ1

Trials

12 trials available for prazosin and Body Weight

ArticleYear
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.
    Gut, 1984, Volume: 25, Issue:1

    Topics: Atenolol; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte

1984
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:4

    Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi

1991
[The antihypertensive response to prazosin, a selective vascular alpha blocker. A multicenter study].
    Revista medica de Chile, 1990, Volume: 118, Issue:2

    Topics: Adult; Aged; Blood Pressure; Body Weight; Chi-Square Distribution; Chile; Female; Humans; Hypertensi

1990
Effectiveness of doxazosin in systemic hypertension.
    The American journal of cardiology, 1989, Jul-15, Volume: 64, Issue:3

    Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Sch

1989
Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
    The American journal of medicine, 1986, May-23, Volume: 80, Issue:5B

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do

1986
Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
    The American journal of medicine, 1986, May-23, Volume: 80, Issue:5B

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Do

1986
Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    The American journal of cardiology, 1987, Aug-01, Volume: 60, Issue:4

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv

1987
Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study.
    Drugs, 1987, Volume: 34 Suppl 3

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials a

1987
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    American journal of hypertension, 1988, Volume: 1, Issue:3 Pt 3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Female; Humans; Hypertension

1988
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
    British journal of clinical pharmacology, 1986, Volume: 21 Suppl 1

    Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Do

1986
Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.
    Journal of clinical pharmacology, 1988, Volume: 28, Issue:12

    Topics: Adolescent; Adult; Aged; Blood Pressure; Body Weight; Dose-Response Relationship, Drug; Female; Fing

1988
Comparative effects of pinacidil and prazosin on blood pressure, weight, plasma volume, the renin-angiotensin-aldosterone system, and the renal kallikrein-kinin system in patients with essential hypertension.
    Journal of clinical hypertension, 1987, Volume: 3, Issue:4

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as To

1987

Other Studies

68 other studies available for prazosin and Body Weight

ArticleYear
The contribution of the mouse tail to thermoregulation is modest.
    American journal of physiology. Endocrinology and metabolism, 2020, 08-01, Volume: 319, Issue:2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Amputation, Surgical; Animals; Body Composition; Body Surfa

2020
Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2019, Volume: 42, Issue:8

    Topics: Adrenergic alpha-1 Receptor Agonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight;

2019
Effects of lisdexamfetamine in a rat model of binge-eating.
    Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:12

    Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Mo

2015
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
    The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:4

    Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glut

2009
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010, Volume: 35, Issue:7

    Topics: Adrenergic alpha-Antagonists; Animals; Appetite Depressants; Benzazepines; Body Weight; Bridged Bicy

2010
Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:3

    Topics: Acetylcholine; Adrenergic alpha-1 Receptor Antagonists; Animals; Benzofurans; Body Weight; Carbachol

2011
Long-term effect of prazosin administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011, Volume: 62, Issue:3

    Topics: Acetylcholine; Adrenergic alpha-1 Receptor Antagonists; Animals; Blood Pressure; Blood Pressure Dete

2011
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
    Journal of neurochemistry, 2002, Volume: 83, Issue:3

    Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Mode

2002
Mitochondrial respiration in muscle and liver from cold-acclimated hypothyroid rats.
    Journal of applied physiology (Bethesda, Md. : 1985), 2003, Volume: 95, Issue:4

    Topics: Adipose Tissue, Brown; Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Animals; Body Weight; C

2003
Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.
    Hepatology (Baltimore, Md.), 2003, Volume: 38, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Diet; Fatty Liver; Hepatocytes; Li

2003
Changes in c-fos expression in the rat heart during morphine withdrawal. Involvement of alpha2-adrenoceptors.
    Naunyn-Schmiedeberg's archives of pharmacology, 2004, Volume: 370, Issue:1

    Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blotting, Western; Body Weight; Drug Administratio

2004
Nocturnal hypertension in mice consuming a high fructose diet.
    Autonomic neuroscience : basic & clinical, 2006, Dec-30, Volume: 130, Issue:1-2

    Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Blood Glucose; Body Weight; Brain Stem; Circa

2006
Paraventricular-coerulear interactions: role in hypertension induced by prenatal undernutrition in the rat.
    The European journal of neuroscience, 2006, Volume: 24, Issue:4

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Corticotropin-Releasing Hormone; Diet

2006
Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats.
    Urologia internationalis, 2006, Volume: 77, Issue:3

    Topics: Animals; Body Weight; Cucurbita; Disease Models, Animal; Drug Therapy, Combination; Male; Phytostero

2006
Coerulear activation by crh and its role in hypertension induced by prenatal malnutrition in the rat.
    The International journal of neuroscience, 2007, Volume: 117, Issue:5

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Corticosterone; Corticotropin-Releasi

2007
Cardiac autonomic receptors: effect of long-term experimental diabetes.
    The Journal of pharmacology and experimental therapeutics, 1984, Volume: 230, Issue:1

    Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Dihydroalprenolol; Heart; Kinetics; Lung; Mal

1984
Caloric intake and Na+-K+-ATPase: differential regulation by alpha 1- and beta-noradrenergic receptors.
    The American journal of physiology, 1984, Volume: 247, Issue:3 Pt 2

    Topics: 4-Nitrophenylphosphatase; Adipose Tissue, Brown; Animals; Body Weight; Desipramine; Diet; Eating; En

1984
Increased alpha 1-adrenergic receptor density in brown adipose tissue of cafeteria-fed rats.
    Bioscience reports, 1984, Volume: 4, Issue:10

    Topics: Adipose Tissue, Brown; Animals; Body Weight; Feeding Behavior; Female; Kinetics; Prazosin; Rats; Rat

1984
Clonidine and prazosin effects in hypernoradrenergic vasodilator-treated and beta-blocker-treated patients.
    Clinical pharmacology and therapeutics, 1981, Volume: 30, Issue:3

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Body Weight; Clonidine; Diastole; Diuretics; Female; Hu

1981
Open assessment of the effect of prazosin on plasma lipids.
    Journal of cardiovascular pharmacology, 1982, Volume: 4 Suppl 2

    Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Cholesterol, HDL; Female; Heart Rate; Humans; Hyper

1982
Effects of experimental diabetes on adrenergic and cholinergic receptors of rat myocardium.
    Diabetes, 1983, Volume: 32, Issue:10

    Topics: Animals; Blood Glucose; Body Weight; Cell Membrane; Diabetes Mellitus, Experimental; Diet, Diabetic;

1983
Terazosin: intravenous safety evaluation in rats.
    Drug and chemical toxicology, 1984, Volume: 7, Issue:5

    Topics: Animals; Antihypertensive Agents; Blepharoptosis; Body Temperature; Body Weight; Dose-Response Relat

1984
Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables.
    Clinical pharmacology and therapeutics, 1983, Volume: 34, Issue:3

    Topics: Adult; Blood Chemical Analysis; Blood Pressure; Body Weight; Cardiac Output; Drug Evaluation; Electr

1983
Effect of prazosin on renal function in chronic congestive cardiac failure.
    The Medical journal of Australia, 1981, Sep-19, Volume: 2, Issue:6

    Topics: Adult; Aged; Body Weight; Creatinine; Gout; Heart Failure; Humans; Kidney; Male; Middle Aged; Prazos

1981
Alterations of alpha 1-adrenergic receptor densities in right and left ventricles of spontaneously hypertensive rats.
    Biological & pharmaceutical bulletin, 1995, Volume: 18, Issue:7

    Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Dogs; Heart Ventricles; Hyperten

1995
Norepinephrine-induced changes in rat heart function, metabolism, and weight are antagonized by carvedilol.
    Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:4

    Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Carbazoles; Carvedilol; Female; Glucosephosphate

1993
Long-term alpha-1 adrenoceptor blockade does not affect plasma atrial natriuretic peptide in hypertensive patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1994, Volume: 26, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Fac

1994
Cyclosporine-induced nephrotoxicity in the rat. The effect of alpha 1-adrenoceptor blockade with prazosin.
    Transplantation, 1993, Volume: 56, Issue:6

    Topics: Animals; Body Weight; Cyclosporine; Kidney; Kidney Transplantation; Male; Prazosin; Rats; Rats, Spra

1993
Selective alpha-1 adrenoceptor blockade and renal sodium handling in humans.
    Journal of clinical pharmacology, 1993, Volume: 33, Issue:11

    Topics: Adult; Blood Pressure; Body Weight; Diuresis; Female; Humans; Infusions, Intravenous; Kidney; Kidney

1993
Carbon monoxide-induced cardiac hypertrophy is not reduced by alpha- or beta-blockade in the rat.
    Toxicology, 1993, Jun-11, Volume: 80, Issue:2-3

    Topics: Animals; Atenolol; Blood Pressure; Body Weight; Carbon Monoxide; Cardiomegaly; Heart Rate; Lung; Mal

1993
Polyunsaturated fatty acids in heart muscle and alpha 1-adrenoceptor binding properties.
    Biochimica et biophysica acta, 1993, Jul-28, Volume: 1178, Issue:1

    Topics: Animals; Binding Sites; Body Weight; Dihydroalprenolol; Epinephrine; Fatty Acids, Unsaturated; Hydro

1993
Altered alpha 1-adrenoceptor binding in intact and adrenalectomized obese Zucker rats (fa/fa).
    Brain research, 1993, Jun-18, Volume: 614, Issue:1-2

    Topics: Adipose Tissue; Adrenalectomy; Animals; Autoradiography; Body Weight; Brain Chemistry; Genotype; Mal

1993
Enhancement of 5-hydroxytryptamine-stimulated phosphoinositide hydrolysis in the rat cerebral cortex by repeated immobilization stress.
    European journal of pharmacology, 1995, Oct-04, Volume: 285, Issue:1

    Topics: Animals; Body Weight; Cerebral Cortex; Hydrolysis; Imipramine; Immobilization; Ketanserin; Male; Pho

1995
Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover.
    Naunyn-Schmiedeberg's archives of pharmacology, 1996, Volume: 353, Issue:4

    Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Body Weight; Dioxane

1996
Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat.
    Prostaglandins, leukotrienes, and essential fatty acids, 1997, Volume: 56, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight;

1997
Effects of aging and food restriction on alpha 1-adrenergic receptors and G-protein in the rat parotid gland.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 1997, Volume: 52, Issue:2

    Topics: Aging; Animals; Binding, Competitive; Body Weight; Cell Membrane; Eating; Epinephrine; Food Deprivat

1997
alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy.
    American journal of hypertension, 1997, Volume: 10, Issue:8

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Body Weight; Dri

1997
Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels.
    Biochemical pharmacology, 1997, Jul-01, Volume: 54, Issue:1

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Enzyme Activation; Heart;

1997
Antihypertensive mechanisms underlying a novel salt-sensitive hypertensive model induced by sensory denervation.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:1 Pt 2

    Topics: Animals; Animals, Newborn; Antihypertensive Agents; Blood Pressure; Body Weight; Calcitonin Gene-Rel

1999
Evaluation of alpha(1)-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2000, Volume: 14, Issue:11

    Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Cre

2000
Effects of low-protein diet on the baroreflex and Bezold-Jarisch reflex in conscious rats.
    Nutritional neuroscience, 2001, Volume: 4, Issue:2

    Topics: Afferent Pathways; Animals; Baroreflex; Blood Pressure; Body Weight; Cardiovascular Physiological Ph

2001
Cardioprotective effect of ischemic preconditioning is preserved in food-restricted senescent rats.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 282, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Aging; Animals; Blood Flow Velocity; Bod

2002
Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption.
    European journal of pharmacology, 2002, May-10, Volume: 442, Issue:3

    Topics: Animals; Aorta, Thoracic; Atenolol; Blood Pressure; Body Weight; Dietary Supplements; Dose-Response

2002
[Prazosin in the combined treatment of moderate to severe hypertension].
    Schweizerische medizinische Wochenschrift, 1979, Jun-30, Volume: 109, Issue:26

    Topics: Adrenergic beta-Antagonists; Body Weight; Diuretics; Dizziness; Drug Therapy, Combination; Female; H

1979
Effect of alpha 1-adrenoceptor blockade on the development of hypertension in the spontaneously hypertensive rat.
    European journal of pharmacology, 1992, Feb-11, Volume: 211, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Biomarkers; Blood Pressure; Body Weight; Hemodynamics; Hypert

1992
Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension.
    Molecular and cellular biochemistry, 1992, May-13, Volume: 112, Issue:1

    Topics: Animals; Body Weight; Cardiomegaly; Diglycerides; Enalapril; Heart Ventricles; Hypertension; Lipids;

1992
Neonatal prazosin exposure reduces ovarian weight and estrogen receptor binding in adult female rats.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 1992, Volume: 10, Issue:5

    Topics: Animals; Animals, Newborn; Body Weight; Brain; Cytosol; Female; Male; Organ Size; Ovary; Prazosin; R

1992
Antagonism of cocaine-induced fetal anomalies by prazosin and diltiazem in mice.
    Reproductive toxicology (Elmsford, N.Y.), 1992, Volume: 6, Issue:2

    Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cocaine; Diltiazem; Dose-Response Relationship, D

1992
Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects.
    Journal of cardiovascular pharmacology, 1991, Volume: 18, Issue:1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Glucose; Blood Pressure; Bod

1991
Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
    Journal of cardiovascular pharmacology, 1991, Volume: 18, Issue:3

    Topics: Adrenergic alpha-Antagonists; Animals; Body Weight; Cholesterol; Cricetinae; Doxazosin; Hydroxymethy

1991
Contractile responses and calcium mobilization in renal arteries of diabetic rats.
    European journal of pharmacology, 1991, Oct-02, Volume: 203, Issue:1

    Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e

1991
Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs.
    Clinical and experimental hypertension. Part A, Theory and practice, 1991, Volume: 13, Issue:4

    Topics: Animals; Blood Pressure; Body Weight; Cardiac Output; Dexamethasone; Dogs; Heart Rate; Hemodynamics;

1991
Dietary sodium restriction and blood pressure response to sympathetic blockade in young versus adolescent spontaneously hypertensive rats.
    Canadian journal of physiology and pharmacology, 1990, Volume: 68, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Clonidine; Diet, Sodium-Restrict

1990
Increases in alpha-but not beta-adrenoceptors in hypertrophied non-infarcted cardiac muscles from rats with chronic myocardial infarction.
    Japanese journal of pharmacology, 1990, Volume: 53, Issue:4

    Topics: Animals; Body Weight; Cardiomegaly; Coronary Vessels; Dihydroalprenolol; Male; Muscle Proteins; Myoc

1990
Diabetes-induced alteration in brain monoamine metabolism in rats.
    The Journal of pharmacology and experimental therapeutics, 1986, Volume: 236, Issue:2

    Topics: Animals; Biogenic Amines; Blood Glucose; Body Weight; Brain; Choline O-Acetyltransferase; Diabetes M

1986
Lack of cardiac alpha 1-adrenoceptor involvement in ethanol-induced cardiac hypertrophy.
    Canadian journal of physiology and pharmacology, 1989, Volume: 67, Issue:3

    Topics: Adrenal Glands; Animals; Behavior, Animal; Body Weight; Cardiomegaly; Catecholamines; Ethanol; Male;

1989
Alpha-blockade on blood pressure and on cardiac noradrenaline content in SHR and DOCA-salt rats.
    The Journal of pharmacy and pharmacology, 1989, Volume: 41, Issue:8

    Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Weight; Desoxycorticosterone; Heart; Hyp

1989
The effect of long-term administration of alpha 1-blocker prazosin on capillary density in cardiac and skeletal muscle.
    Pflugers Archiv : European journal of physiology, 1989, Volume: 415, Issue:3

    Topics: Animals; Blood Pressure; Body Weight; Capillaries; Coronary Circulation; Coronary Vessels; Heart; He

1989
The field-stimulated vas deferens of the streptozotocin-diabetic mouse: effects of prazosin, alpha, beta-methylene ATP, and variation of stimulation parameters.
    Journal of neural transmission, 1989, Volume: 77, Issue:2-3

    Topics: Adenosine Triphosphate; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Electr

1989
Hypertensinogenic factors and renal alpha-adrenoceptors in young SHR and WKY rats.
    Life sciences, 1987, Nov-16, Volume: 41, Issue:20

    Topics: Animals; Blood Pressure; Body Weight; Desoxycorticosterone; Hypertension; Kidney; Male; Prazosin; Ra

1987
Combined neurohumoral block modulates pulmonary vascular P/Q relationship in conscious dogs.
    The American journal of physiology, 1988, Volume: 255, Issue:5 Pt 2

    Topics: Animals; Atropine; Autonomic Nervous System; Blood Pressure; Body Weight; Captopril; Cardiac Output;

1988
Long-term experience with terazosin for treatment of mild to moderate hypertension.
    The American journal of medicine, 1986, May-23, Volume: 80, Issue:5B

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Dru

1986
Overall safety of terazosin as an antihypertensive agent.
    The American journal of medicine, 1986, May-23, Volume: 80, Issue:5B

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea

1986
Postnatal treatment of rats with adrenergic receptor agonists or antagonists influences differentiation of sexual behavior.
    Hormones and behavior, 1987, Volume: 21, Issue:4

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Body Weight; Clo

1987
The influence of atenolol and prazosin on serum lipids and atherosclerosis in minipigs fed a hyperlipidemic diet.
    General pharmacology, 1988, Volume: 19, Issue:5

    Topics: Animals; Arteriosclerosis; Atenolol; Body Weight; Cholesterol, Dietary; Diet; Female; gamma-Glutamyl

1988
Comparison of cicletanine with other antihypertensive drugs in SHR-SP models.
    Drugs under experimental and clinical research, 1988, Volume: 14, Issue:2-3

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Diuresis; Di

1988
Pre- and neonatal exposure of the Dahl rat to NaCl: development and regional distribution of myocardial alpha 1-adrenergic and cholinergic receptor sites.
    Journal of the autonomic nervous system, 1986, Volume: 16, Issue:2

    Topics: Animals; Animals, Newborn; Blood Pressure; Body Weight; Cell Membrane; Female; Heart; Heart Atria; H

1986
Hepatic adrenergic receptors in the genetically diabetic C57 BL/KsJ (db/db) mouse.
    The International journal of biochemistry, 1987, Volume: 19, Issue:12

    Topics: Animals; Body Weight; Cell Membrane; Diabetes Mellitus, Experimental; Dihydroalprenolol; Heterozygot

1987